Biotechnology Press Release
|04/28/2020 - 12:51||
Hamilton and IMCS Jointly Develop affinityPure STAR Assay Ready Workstation to Aid Coronavirus Research
Reno, Nev. (April 28, 2020) – Hamilton Company and Integrated Micro-Chromatography Systems (IMCS) introduce the affinityPure™ STAR assay ready workstation as part of their ongoing collaboration. The solution, based on Hamilton’s Microlab® STAR™ automated liquid handler, is pre-configured and qualified to automate high-throughput, small-scale affinity purification workflows.
|04/28/2020 - 10:23||
Purdue ranked 3rd nationally in startup creation
IPWatchdog report covering 11-year period of technology transfer activities of nearly 200 universities and research entities lists Purdue University just behind Columbia and MIT
|04/28/2020 - 10:14||
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Dr. Walter joins Relmada from REGENXBIO Inc., where he most recently served as Vice President of Regulatory Affairs, responsible for the global regulatory strategy, operations, pharmacovigilance, and medical writing for the company's portfolio of AAV-based gene therapy development candidates.
|04/28/2020 - 09:49||
Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm
NOTTINGHAM, U.K., and PITTSBURGH, April 28, 2020 – A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc.
|04/28/2020 - 09:04||
Making work-at-home work: A little more help
Those were just a few of the tips and tricks your UW–Madison colleagues offered for adjusting to changes in work and home life.
|University of W...|
|04/28/2020 - 07:35||
Endesa donates a further 376,000 masks to Caritas, the Altius Foundation and various Spanish regions
Endesa donates a further 376,000 masks to Caritas, the Altius Foundation and various Spanish regions.
|04/28/2020 - 05:00||
Norwich Research Park Biorepository goes live with new laboratory management system
A biobank for health research based on the Norwich Research Park has successfully gone live with a new laboratory management system and is now supporting Norfolk’s COVID-19 research efforts.
|04/28/2020 - 00:37||
CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors
Ms. Gilbert brings to CytomX extensive leadership experience in the biopharmaceutical industry, with particular expertise in corporate and business development, legal, compliance and corporate strategy.
|04/28/2020 - 00:11||
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Engineering and Evaluation of Novel AAV Serotypes for Gene Delivery to the Central Nervous System – Abstract #23 Oral Presentation – Tuesday, May 12 ; 10:30AM ET Engineered Zinc Finger Protein Transcription Factors Efficiently and Specifically Reduce Mouse and Human Prion Expression – Abstract #296 Poster Presentation – Tuesday, May 12 ; 5:30PM ET Novel Therapeutic Approach for Parkinson’s Disease: Engineered Zinc Finger Protein Transcription Factors Efficiently and Specifically Reduce Alpha-Synuclein Expression – Abstract #711 Poster Presentation – We
|04/27/2020 - 21:49||
Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials
BOSTON--( )--Apr. 28, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting. The meeting will be held exclusively via webcast on June 3, 2020 at 9:30 a.m., Eastern Time. Shareholders as of April 9, 2020, the record date for the meeting, may attend the meeting by visiting www.meetingcenter.io/207970612 and following the instructions in the proxy materials.
|04/27/2020 - 19:19||
Teams from Wisconsin, New York search for molecular clues to defeat COVID-19
In the center of the COVID-19 pandemic, hospitals are racing to maintain quality care for patients with severe disease while facing a shortage of resources and limited understanding of the novel coronavirus.
|University of W...|
|04/27/2020 - 18:28||
A step toward a more efficient way to make gene therapies to attack cancer, genetic disorders
A UCLA-led research team today reports that it has developed a new method for delivering DNA into stem cells and immune cells safely, rapidly and economically. The method, described in the journal Proceedings of the National Academy of Sciences, could give scientists a new tool for manufacturing gene therapies for people with cancer, genetic disorders and blood diseases.
|04/27/2020 - 14:28||
Applied BioMath, LLC Announces Collaboration with Xilio Therapeutics
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xilio Therapeutics. Applied BioMath will continue work on semi-mechanistic pharmacokinetic/pharmacodynamic models to support Xilio development programs.
|04/27/2020 - 12:27||
Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients
Following a review by the Independent Data Monitoring Committee (IDMC) of all available Phase 2 and Phase 3 data, the trial will be immediately amended so that only “critical” patients continue to be enrolled to receive Kevzara 400 mg or placebo.
|04/27/2020 - 12:23||
Martin Lab Lands Major Massachusetts Tech Transfer Award
Craig Martin The Craig Martin Lab in chemistry recently received an Acorn Award from the Massachusetts Technology Transfer Center (MTTC), one of 13 innovation seed-funding $15,000 grants given statewide intended “to support the demonstration of the viability of a technology developed at Massachusetts research universities.”
|University of M...|
|04/27/2020 - 10:44||
- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
Based on a recommendation by the independent Data Monitoring Committee to stop the trial early, the trial will be modified to allow all patients to receive Libtayo for this investigational use.
|04/27/2020 - 08:24||
ICYMI: Expert Encourage Increasing Biosimilar Use to Lower Health Care Costs; Study Finds Biosimilars Could Lower Employers Insurance Costs
Washington, DC — As the country and world battles a pandemic, the issue of mounting health care costs continues to burden American companies, patients and taxpayers.
|04/27/2020 - 01:05||
Meridian Bioscience Simplifies COVID-19 Sample Prep and Eliminates Dependence on Reagents in Short Supply
To date, most COVID-19 molecular assays require laboratories to first isolate and purify the SARS-CoV-2 viral RNA from a patient sample (saliva or nasopharyngeal). This step is not only complex and time consuming, but also adds to the overall cost of the COVID-19 assay.
|04/27/2020 - 00:40||
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis.
|04/27/2020 - 00:20||
Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
Seasoned industry executive with experience leading global joint preservation and restoration businesses.
|04/26/2020 - 01:34||
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE Technology For Patients With Multiple Myeloma
The NDA is supported by pivotal data from the Phase 3 COLUMBA (MMY3012) study – a randomized open label study – that included a non-inferiority comparison of daratumumab SC formulation versus daratumumab IV administration in patients with multiple myeloma who had received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or whose disease was refractory to both PI and IMiD.
|04/25/2020 - 19:53||
Engineers develop precision injection system for plants
Microneedles made of silk-based material can target plant tissues for delivery of micronutrients, hormones, or genes.
|04/24/2020 - 18:20||
CIRM Board Funds its First Clinical Study for COVID-19
Oakland, CA – Today the governing Board of the California Institute for Regenerative Medicine (CIRM) continued its commitment to help with the coronavirus pandemic by awarding $749,999 to Dr. John Zaia at City of Hope. He will be conducting a clinical study to administer blood plasma from recovered COVID-19 patients to treat those with the virus. This marks CIRM’s first clinical study for COVID-19 after approving emergency funding a month earlier.
|04/24/2020 - 17:34||
NMSU biology student receives prestigious research fellowship
Valerie Brewer is double majoring in conservation ecology and biology while minoring in genetics and biotechnology at New Mexico State University. She is among the top young scholars in the nation to earn a National Science Foundation Graduate Research Fellowship, the country’s oldest fellowship that directly supports graduate students in various STEM fields.
|New Mexico Stat...|
|04/24/2020 - 08:46||
Thermo Fisher Scientific and Hamilton Company Introduce Forensic Laboratory-Qualified Automated Nucleic Acid Extraction Platform
ID NIMBUS Presto Assay Ready Workstation Integrates Thermo Scientific KingFisher Presto Purification System with Hamilton Microlab NIMBUS for Rapid Processing of Casework Samples.
|Thermo Fisher S...|